FNY Partners Fund’s Alexion Pharmaceuticals ALXN Stock Holding History

FNY Partners Fund’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-5	Closed	-$1K	–	1557
2016 Q4	$1K	Buy	+5	New	+$612	﹤0.01%	571

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

FNY Partners Fund's ALXN Position: Q1 2018 in Review

FNY Partners Fund sold out of Alexion Pharmaceuticals (ALXN) in Q1 2018, closing a stake of 600 shares — an estimated $71K sold.

FNY Partners Fund first reported a position in ALXN in Q4 2016 and held it in 4 quarters. The position peaked at $71K in Q4 2017. 597 funds tracked by Wall St. Rank hold ALXN as of Q1 2018.

FNY Partners Fund reported no remaining Alexion Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
FNY Partners Fund sold 600 Alexion Pharmaceuticals shares in Q1 2018, an estimated $71K.
FNY Partners Fund first reported a position in Alexion Pharmaceuticals in Q4 2016 and held it in 4 quarters.
FNY Partners Fund's Alexion Pharmaceuticals position peaked at $71K in Q4 2017.
597 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2018.

Based on FNY Partners Fund's 13F filing for Q1 2018, filed 18 Apr 2018.